644985-24-0

Usage

Uses

4-Bromo-2,3-difluorobenzaldehyde is used as pharmaceutical intermediates.

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 156682-52-9 1,4-dibromo-2,3-difluoro-benzene 
• 867366-94-7 (2,3-difluoro-1,4-phenylene)bis(trimethylsilane) 
• 367-11-3 ortho-difluorobenzene 
• 38573-88-5 1-bromo-2,3-difluorobenzene 

Downstream Products

• 867366-95-8 C₁₄H₆BrClFNO₂ 
• 1068603-93-9 5-(3-bromo-2-fluoro-6-formyl-phenoxy)-N,N'-di-tert-butyl-isophthalamide 
• 910825-41-1 C₁₅H₇BrF₃NO₂ 
• 162744-55-0 (4-bromo-2,3-difluorophenyl)methanol 

Relevant academic research and scientific papers

(AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.

NOVEL ANTIBIOTICS AND METHODS OF USING SAME

The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subjec

LIQUID-CRYSTALLINE COMPOUND HAVING DIFLUOROMETHYLENEOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT

To provide a liquid crystal compound satisfying at least one of physical properties such as high stability to light, a high clearing point, a low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large dielectric anisotropy, a large dielectric constant in a minor axis direction, a suitable elastic constant and excellent compatibility; a liquid crystal composition containing the compound; and a liquid crystal display device including the composition. The compound is represented by formula (1). For example, R1 is alkyl having 1 to 15 carbons, ring A1 to ring A4 are 1, 4-cyclohexylene or 1, 4-phenylene, Z1 to Z4 are a single bond, - (CH2)2-, -COO- or -CH2O-, X1 is halogen, -C=N, -CF3 or -OCF3, L1 and L2 are hydrogen or fluorine, Y1 and Y2 are fluorine; a, b, c and d each are 0 or 1, and a sum thereof is 1 or 2.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Heterocyclic antiviral compounds

The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R1, R2, R3, R4, R5, are as defined herein.

Heterocyclic reverse transcriptase inhibitors

The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where R1, R2 and R3, are as defined herein.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R1-R5, R7a, R7b, R7c, R8-R10, X1, X2 m, n, o and p are as defined herein.